Markets

Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4%

Esperion Therapeutics, Inc.ESPR was a big mover last session, as the company saw its shares jump a little above 10% on the day. The move came after a regulatory pathway for its cholesterol-lowering combination was approved by the Food and Drug Administration. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 53% in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved lower over the same timeframe. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Esperion Therapeutics currently carries a Zacks Rank #3 (Hold).

Esperion Therapeutics, Inc. Price

Esperion Therapeutics, Inc. Price | Esperion Therapeutics, Inc. Quote

A better-ranked stock in the Medical - Drugs industry is Aerie Pharmaceuticals, Inc. AERI holding a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Is ESPR going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report

Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ESPR AERI

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More